Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing and marketing company headquartered in India.
Intas's success and incessant growth lies in clinical execution of successful and strategic moves made in the areas of manufacturing, R & D, Biotechnology and global operations over three decades. As of 31st of March 2012, Intas has grown to be a ~$525 million organization with a revenue growth of ~30% CAGR over the last 5 years and a profit growth of over 50% CAGR over the same period. Intas is now ranked as the 12th largest pharmaceutical company in the domestic market (as per IMS Health India, Secondary Stockist Audit (SSA), February, 2013).
In the domestic market, Intas is the 4th largest corporate in Indian Chronic Pharma Market with a market share of more than 5%. It also has presence in central nervous system (CNS), cardiovascular system (CVS), diabetology, gastroenterology and pain management. Recently, Intas has extended its presence into other therapy areas such as gynecology, infertility and respiratory care.
Besides rapidly growing domestic prominence, Intas is also present in more than 70 countries worldwide with robust sales, marketing and distribution infrastructure in markets like North America, Europe, Central & Latin America, Africa, Australia, New Zealand, Asia - Pacific as well as CIS and MENA countries.
Intas's global strategy includes alliances with leading Global Pharma Companies for development and distribution of products as well as direct product distribution.
Its subsidiary, Intas Biopharmaceuticals Limited, has made substantial investments in the development, manufacturing and marketing of products based on biotechnology (biosimilars) in chronic therapy areas including oncology and nephrology.
Continual R & D initiatives have strengthened niche and complex product offerings in India and International markets. Commercialized in India, three pharmaceutical formulations are based on the novel lipid based drug delivery system with studies ongoing to extend these products to International markets.
Intas has made strategic investments in ten manufacturing facilities, globally. Between them, these facilities have received approvals from various prominent international regulatory bodies, including U.S. Food and Drug Administration (FDA).